In conclusion, the application of Chimeric Antigen Receptor T cell therapy targeting EpCAM in gastric cancer faces formidable challenges related to tumor resistance mechanisms. From genetic alterations affecting EpCAM expression to the immunosuppressive tumor microenvironment, a multifaceted understanding of these mechanisms is crucial for devising effective therapeutic strategies. Combining immunotherapies, exploring precision medicine approaches, and leveraging insights from ongoing clinical trials represent avenues for enhancing the clinical success of CAR T cell therapy in gastric cancer. As research continues to unravel the complexities of tumor resistance, the integration of innovative strategies holds promise for improving outcomes and advancing the field towards more personalized and effective treatments.
The future of EpCAM-targeted CAR T cell therapy in gastric cancer holds exciting possibilities. Emerging technologies, including advancements in synthetic biology, gene editing, and novel targeting strategies, are likely to shape the next generation of CAR T cell therapies. The exploration of dualtargeting CAR constructs, incorporation of logic-gated systems, and innovations in manufacturing processes will contribute to enhancing therapeutic efficacy and overcoming current challenges. Continued investment in research and development is crucial for unlocking the full potential of CAR T cell therapies in the treatment of gastric cancer.